ArticleESMO open2024

A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101).

N Lakhani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.